Phase 3 Trial Results
Tenax Therapeutics Presents Phase 3 LEVEL Trial Results at ESC Congress 2026
Anonymous
Tenax Therapeutics presented Phase 3 data for TNX-103, an oral heart drug, at Europe's largest cardiology conference in 2026. The drug showed a 26.3-meter improvement in walking distance and cut a key heart-stress marker (NT-proBNP) by 47% versus placebo Globe Newswire. But the trial's main goal — a statistically significant improvement in the standard 6-minute walk test — was not met.
TNX-103 is being tested in patients with pulmonary hypertension caused by heart failure with preserved ejection fraction (PH-HFpEF), a condition where the heart struggles to pump blood efficiently. The LEVEL trial enrolled 241 patients across 41 sites in the US and Canada Yahoo Finance. Results suggest the drug may help patients move farther and reduce heart strain, even without hitting the primary target.
The Mixed Results of a Heart Drug Test
TNX-103 delivered strong secondary benefits in the LEVEL trial. Patients taking the drug walked 26.3 meters farther in six minutes than those on placebo Globe Newswire. The drug also reduced right ventricular systolic pressure (RVSP) by 4.9 mmHg and lowered NT-proBNP levels by 47%, a protein that indicates heart stress Barchart.
However, these gains were not enough to meet the trial's primary endpoint. The 6-minute walk distance improvement did not reach statistical significance, meaning it could have happened by chance Yahoo Finance. This is a setback for Tenax, as pharmaceutical regulators typically require the main goal to be met for approval.
What PH-HFpEF Patients Face Today
Pulmonary hypertension due to heart failure with preserved ejection fraction is a serious condition with few treatment options. These patients have lungs under high pressure because the heart cannot relax properly between beats. The condition limits exercise and causes shortness of breath, making walking tests a real measure of quality of life.
TNX-103 works by strengthening the heart's contraction and helping it relax better — properties that make sense for this disease. The 26.3-meter walking improvement could help patients perform daily activities like climbing stairs or shopping. For a disease with limited therapies, even secondary benefits matter to physicians and patients.
What Comes Next for Tenax and TNX-103
Missing the primary endpoint complicates Tenax's path to FDA approval. The company will need to discuss next steps with regulators. Options include seeking accelerated or conditional approval based on secondary data, running another trial, or redesigning the study to use a different primary endpoint Globe Newswire.
Presenting at ESC Congress — one of the world's largest cardiology meetings — keeps TNX-103 in the spotlight. The secondary benefits and safety data may interest cardiologists treating PH-HFpEF patients. Tenax's next announcement will likely detail whether the company pursues regulatory talks or additional trials.
Sentiment
NeutralNEGATIVENEUTRALPOSITIVE
Publishers
4
Articles
4
Reach
4
Topics
A
AnonymousAuthor
